KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit

類似資料

• KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
  著者:: Pacheco, Jose M.
  出版事項: (2019)
• KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment
  著者:: Cummings, Amy Lauren, 等
  出版事項: (2019)
• Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold
  著者:: Xu, Zhijie, 等
  出版事項: (2020)
• KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1–49%
  著者:: Morgensztern, Daniel
  出版事項: (2019)
• Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
  著者:: Nishio, Shin, 等
  出版事項: (2020)